The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy

This study tests whether a specialized PET/CT scan using a radioactive tracer called 68Ga-FAPI (which attaches to activated cells in tumor tissue) can better detect and evaluate treatment response in people with advanced, inoperable liver cancer (hepatocellular carcinoma) undergoing systemic therapy. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced, unresectable liver cancer (HCC — confirmed by biopsy or clinical criteria) - You are willing and able to follow the study procedures **You may NOT be eligible if...** - You have serious heart or lung failure, severe bone marrow suppression, or severe liver or kidney disease - You have complete bowel obstruction or intestinal perforation - You are pregnant, possibly pregnant, or breastfeeding - You are unable to comply with study procedures Talk to your doctor to see if this trial is right for you.